Vaccine
| Autor: | Martins Netto, Eduardo, Takahashi, Denise, Oliveira, Maria de Fátima Santos Paim de, Barbosa, Paulo José Bastos, Ferraz, Neide, Paixão, Ariene, Oyafuso, Luiza Keiko, Bortoletto, Cecília, Matos, Denise, Paixão, Maurício, Silva, Anete Olivieri Pessoa da, Badaró, Roberto José da Silva |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: | |
| Zdroj: | Repositório Institucional da UFBA Universidade Federal da Bahia (UFBA) instacron:UFBA |
| DOI: | 10.1016/j.vaccine.2006.03.047 |
| Popis: | RESTRITO Submitted by Santiago Fabio (fabio.ssantiago@hotmail.com) on 2012-07-31T17:45:44Z No. of bitstreams: 1 AA.pdf: 179934 bytes, checksum: 97b1bc3106cc5384dd4948015de9b412 (MD5) Made available in DSpace on 2012-07-31T17:45:44Z (GMT). No. of bitstreams: 1 AA.pdf: 179934 bytes, checksum: 97b1bc3106cc5384dd4948015de9b412 (MD5) Previous issue date: 2006 The treatment effect against psoriasis of an antigen (delipidated, deglycolipidated form of M. vaccae-PVAC) was investigated. One hundred and sixty-five patients were enrolled in three arms (50 or 15 μg or placebo), each receiving a total of two intradermal injections (days 0 and 21). At week 12, a 75% decrease in psoriasis area and severity index was similar among the studied groups (13, 9 and 18%, p = 0.429). The overall incidence of adverse events was significantly higher in the PVAC treated groups when compared to placebo (98.2, 87.3 and 70.9%; p < 0.001) largely due to local reactions that were limited for the most part to grades 1 and 2 in severity and were self-limiting. Despite its overall safety, PVAC was not clearly indicated to be superior to placebo in the treatment of psoriasis in this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|